MedTrace Logo

Aerobic Exercises vs Device Guided Breathing on Gestational Hypertension

NCT04352374 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2020-04-20

No results posted yet for this study

Summary

Aim To compare between the effect of aerobic exercise versus device guided breathing (DGB) on blood pressure in gestational hypertensive patients. Participants and Methods Randomized controlled trial, which included 60 singleton pregnant women (at 21-week gestation) diagnosed with gestational hypertension. They were divided into two groups: group (A) received aerobic exercise with a treadmill twice a week, for 45 minutes; and group (B) received Device guided breathing exercise for at least 40 min per week, with each session lasting at least 10 min. Assessment of the systolic blood pressure (SBP) and diastolic blood pressure (DBP) for all participants in the two studied groups (A, B) was carried out at begining of the study and at week-36 of gestation with mercury column sphygmomanometer.

Conditions

  • Hypertension ,Pregnancy

Interventions

OTHER

Aerobic exercise

a Low-Intensity Aerobic Exercise with Borg scale RPE at 11.

DEVICE

Device guided breathing

The device consists of a control box, headphones and a respiratory rate monitor attached as a sensor belt around the user's chest.

Sponsors & Collaborators

  • Cairo University

    lead OTHER

Principal Investigators

  • Asmaa M Elbandrawy, Assis prof · Cairo University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
25 Years
Max Age
35 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-01-01
Primary Completion
2020-03-01
Completion
2020-04-01

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04352374 on ClinicalTrials.gov